ESR1 and breast carcinoma: In addition, a recent study revealed that DOT1L is a novel cofactor of estrogen receptor α (ERα), acting to regulate estrogen target genes, and that DOT1L inhibition suppresses proliferation of antiestrogen-resistant breast cancer cells [23].